EN DE
Watch VivoSim Labs, Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

VivoSim Labs, Inc. (VIVS) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of VivoSim Labs, Inc. stock $0.12, price $0.12, that is 5.5% below the price, quality 31 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US68620A3023

VL VivoSim Labs, Inc. logo Thin data Nov 16, 2026

VivoSim Labs, Inc.

VIVS · US

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Fair value $0.1169 · Fairly valued 
Negative equity (buybacks among others) 
Insiders bought $2,800 (6M) 
Revenue last quarter 51% below a year ago. 
Quality 31/100 
Falling price (downtrend) 
Weak Growth (revenue 3y −29.3 %/yr in USD) 
Negative free cash flow 
Trails peers (1/5) 
Narrow moat 23/100 · thin data
Thin data 
Estimate
Watch VivoSim Labs, Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$96.36 $0.1237 Fair Value $0.1169 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range $0.1237 – $96.36 · fair‑value band $0.0876 – $0.1461 · the $0.1237 price screens above the $0.1169 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow VivoSim Labs in your weekly email

Every Wednesday you see whether VivoSim Labs is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine.

Show moreShow less

It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models.

The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease.

In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025.

VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Stock analysis

VivoSim Labs, Inc. (VIVS) currently trades at $0.1237, while our estimate is $0.1169, so the stock looks roughly fairly valued today (gap 5.8%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.0876 (bear) to $0.1461 (bull), the price of $0.1237 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

VivoSim Labs, Inc. reported revenue of $131K in FY2026 versus $1.5M in FY2022, a compound −45.6%/yr. Reported net income was −$13.8M in FY2026.

Key figures

Market cap $2.6M Micro · P/S ratio 23.0 · EPS (TTM) $−4.47 · Return on equity −343% · Return on assets (EBIT) −119% (5-year average) · Operating margin −10,117% · Revenue (TTM) $112K · Revenue growth (YoY) −51.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (low confidence).

What moves the price

The share trades about 96% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −6%, VIVS screens cheaper than that median.

Fair Value

Bear $0.0876 Fair Value $0.1169 Bull $0.1461
Price $0.1237 · Downside -5.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 28
Are margins and returns getting better?
Cashflow 30
Do the profits arrive as real cash?
Financial strength 50
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 9
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $2,800, on Aug 31, 2026.

  • BuyTony Serge LialinChief Commercial Officer10,000 shares at $0.2800$2,800Aug 31, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−9.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−29.3%
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−977.9% (2020) → −8,567.9% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch VIVS, get fair value alerts →

Compare VivoSim Labs, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 31 · Below median
Fair Value upside −5.5% · Top 25%
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −187.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −51.4% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 23.02× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)26 · sector 1
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs VIVS
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs VIVS
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs VIVS
argenx SE ARGX $950.95 $908.40 −4% vs VIVS
CSL Limited CSL A$199.55 A$186.49 −7% vs VIVS
Moderna, Inc MRNA $215.27 $135.64 −37% vs VIVS
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs VIVS
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs VIVS
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs VIVS
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs VIVS

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

VivoSim Labs, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "VivoSim Labs, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/VIVS

Frequently asked questions

Is VivoSim Labs, Inc. (VIVS) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is $0.1169 versus a price of $0.1237, about 6% lower (fairly valued).
What is the fair value of VIVS?
Our estimate for VivoSim Labs, Inc. is $0.1169 (as of Nov 16, 2026), built from audited fundamentals. The current price: $0.1237.
What is the quality score of VIVS?
VivoSim Labs, Inc. has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for VivoSim Labs, Inc. (VIVS)?
Our calculated price target is the estimate of $0.1169 (as of Nov 16, 2026). Cautious scenario $0.0876, optimistic scenario $0.1461. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the VivoSim Labs, Inc. stock forecast for 2026?
Our estimate puts fair value at $0.1169, about 6% lower versus a price of $0.1237 (fairly valued). Cautious scenario $0.0876, optimistic scenario $0.1461. The calculation is refreshed regularly with new filings.
What is the revenue of VivoSim Labs, Inc. (VIVS)?
VivoSim Labs, Inc. reported trailing-twelve-month revenue of about $112K (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of VivoSim Labs, Inc. (VIVS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For VivoSim Labs, Inc. it is $0.1169 per share (as of Nov 16, 2026), against a price of $0.1237.
Is VivoSim Labs, Inc. stock overvalued or undervalued in 2026?
As of Nov 16, 2026, VIVS trades above its calculated fair value: price $0.1237, fair value $0.1169, a gap of about −6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VIVS?
No. The price is what the market pays today ($0.1237); the fair value is what the company's own numbers justify ($0.1169). For VivoSim Labs, Inc. the two are $0.0068 per share apart. That gap is exactly why we show both numbers side by side.
How much is VivoSim Labs, Inc. worth?
The market values VivoSim Labs, Inc. at about $2.6M (market capitalisation, as of Nov 16, 2026). Per share that is $0.1237; our models calculate a fair value of $0.1169 per share.
What do the bullish and bearish scenarios say about VIVS?
Our models span a range for VivoSim Labs, Inc.: cautious scenario $0.0876, base $0.1169, optimistic $0.1461 per share (as of Nov 16, 2026, price $0.1237). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of VivoSim Labs, Inc. (VIVS)?
Balance-sheet figures for VivoSim Labs, Inc. (as of Nov 16, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is VIVS from its 52-week high?
VivoSim Labs, Inc. trades at $0.1237, about 96% below its 52-week high of $2.92 and at the low of $0.1237 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1169 is for.
Which stocks are comparable to VivoSim Labs, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is VivoSim Labs, Inc. stock attractive at the current price?
The data as of Nov 16, 2026: price $0.1237, calculated fair value $0.1169 (−6%), Quality Score 31/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. VivoSim Labs, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of VivoSim Labs, Inc. (VIVS)?
The closing price on Nov 16, 2026 was $0.1237. Our estimate is $0.1169, about 6% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with VivoSim Labs, Inc. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of VivoSim Labs, Inc.

How large is the market capitalisation of VivoSim Labs, Inc. (VIVS)?
The market capitalisation of VivoSim Labs, Inc. is $2.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of VivoSim Labs, Inc. (VIVS)?
The price-to-sales ratio of VivoSim Labs, Inc. is 23.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of VivoSim Labs, Inc. (VIVS)?
Earnings per share at VivoSim Labs, Inc. are $−4.47. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of VivoSim Labs, Inc. (VIVS)?
The return on equity (ROE) of VivoSim Labs, Inc. is −343% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of VivoSim Labs, Inc. (VIVS)?
On an EBIT basis the return on assets of VivoSim Labs, Inc. is −119% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of VivoSim Labs, Inc. (VIVS)?
The operating margin of VivoSim Labs, Inc. is −10,117% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at VivoSim Labs, Inc. (VIVS)?
Revenue at VivoSim Labs, Inc. is down 51.4% versus a year earlier (3y avg −29.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does VivoSim Labs, Inc. (VIVS) generate?
The free cash flow of VivoSim Labs, Inc. is −$10.8M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does VivoSim Labs, Inc. (VIVS) hold?
VivoSim Labs, Inc. holds more cash than debt, $4.6M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch VivoSim Labs, Inc. in the live analysis

One click puts VivoSim Labs, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.